IL5 and asthma: As tissue eosinophil numbers were not increased in stable‐state T2‐high severe asthma, the efficacy of anti‐IL5/IL‐5Rα and anti‐IL‐4Rα therapy on exacerbations may be due to their effects on systemic rather than tissue eosinophils, preventing recruitment and further trafficking to the tissue during exacerbations.